Miscellaneous

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultrelapse progression or death (progression free survival PFS)

melanoma

Interferon alpha
EORTC18991 (Eggermont), 2008   PEG IFN alpha-2b (I M)observationadjuvantsuggesting-13%
EORTC18871/DKG 80-1 stage III   rIFN alpha-2bobservation -
ipilimumab
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias conclusive -24%
nivolumab
CheckMate 238 subgroup IIIB-C   nivolumabipilimumabsuggesting-35%
pembrolizumab
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias conclusive -43%
trametinib + dabrafenib
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting-53%
vemurafenib
BRIM 8 (cohort IIIC)   vemurafenibplacebonegative-20%

sarcoma

pazopanib
PALETTE (van der Graaf), 2012      NCTpazopanib placebosuggesting